Dr. Birrer on Checkpoint Inhibitors for Endometrial Cancer

Michael Birrer, MD, PhD
Published Online: Monday, Jun 19, 2017



Michael Birrer, MD, PhD, UAB Comprehensive Cancer Center in Alabama, discusses checkpoint inhibitors for patients with endometrial cancer.

Across all tumor types, there is a growing excitement around checkpoint inhibitors, which is the case in endometrial cancer as well, explains Birrer. There is a subset of patients with endometrial cancers that are microsatellite instability-high (MSI-H).

Recently, there was an approval for MSI-H tumors; however, there is still a study investigating what the response rate is for patients with endometrial cancer since the approval was based on very few patients, states Birrer.
 


Michael Birrer, MD, PhD, UAB Comprehensive Cancer Center in Alabama, discusses checkpoint inhibitors for patients with endometrial cancer.

Across all tumor types, there is a growing excitement around checkpoint inhibitors, which is the case in endometrial cancer as well, explains Birrer. There is a subset of patients with endometrial cancers that are microsatellite instability-high (MSI-H).

Recently, there was an approval for MSI-H tumors; however, there is still a study investigating what the response rate is for patients with endometrial cancer since the approval was based on very few patients, states Birrer.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Precision Medicine: The Evolving Role of Genomics and Proteomics in Cancer Treatment: Current and Emerging Roles for Molecular Testing Technologies: Real-World Application into PracticeAug 29, 20171.5
Community Practice Connections™: Oncogenic Tumor Board in NSCLC: Targeting Driver Mutations to Maximize Therapeutic OutcomesAug 31, 20171.5
Publication Bottom Border
Border Publication
$emailPop$